BioSpace News Archive

Ribometrix announced today the promotion of Manjunath (Manju) Ramarao, Ph.D., to chief scientific officer.

Nuance Pharma announced, that it has entered into an exclusive license and supply agreement with Bavarian Nordic on the development and commercialization of MVA-BN® RSV against respiratory syncytial virus in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries.

AlzeCure Pharma AB announced that an abstract with new Alzstatin data has been accepted for a poster presentation at the 2nd Swedish Meeting for Alzheimer Research which is held on April 21, 2022, at the Karolinska Institutet in Stockholm.

Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced the results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout.

SQZ Biotechnologies announced that it has been awarded a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences, a division of the National Institutes of Health.

Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on Monday, March 28, 2022 at 12:30 p.m. ET.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 24, 2022 after the U.S. financial markets close.

Eliem Therapeutics, Inc. announced that Bob Azelby, Eliem’s president and chief executive officer, will present at Stifel’s 2022 CNS Days being held virtually on Tuesday, March 29, 2022 at 9:30 AM ET.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first two cohorts of its randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington’s disease.